Company Overview
About Exin Therapeutics
Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.
Business Model & Competitive Advantage
Exin's AI neurotherapeutics platform addresses the target identification challenge that makes central nervous system drug development the most difficult therapeutic area: the brain's complexity (100 billion neurons with 100 trillion synaptic connections expressing 30,000+ genes) means that identifying which genes, circuits, or signaling pathways to target for a given neurological condition requires integrating multi-modal data types that traditional bioinformatics pipelines analyze separately. Exin's multimodal AI (simultaneously training on electrophysiology (neural firing patterns), behavioral data (movement, seizure frequency, social behavior), and transcriptomics (gene expression profiles)) learns the relationships between molecular interventions and functional neural outcomes — enabling the company to predict which genetic therapy strategies will modulate neural activity in therapeutically beneficial directions before expensive and time-consuming in vivo studies.
Competitive Landscape 2025–2026
In 2025, Exin Therapeutics competes in the AI drug discovery, gene therapy, and CNS therapeutics market with Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery, $400M+ raised), Invaio Sciences (agricultural neuroscience, different sector), and Prevail Therapeutics (NASDAQ: PRVL, AAV gene therapy, acquired by Eli Lilly for $1.04B) for AI-powered neurological disease genetic therapy discovery and development adoption. The Philippines laboratory investment ($25M commitment) represents a significant geographic and infrastructure bet on building neurotherapeutics research capacity in Southeast Asia. The provisional patent filings validate novel intellectual property in the AI-neural target identification space. The 2025 strategy focuses on advancing the epilepsy genetic therapy lead program toward formal IND filing, building the human neural organoid validation system for translational prediction accuracy, and developing the Parkinson's disease gene therapy pipeline leveraging the multimodal AI platform's dopaminergic circuit modeling.
Company Timeline
Major milestones in Exin Therapeutics's journey
Leadership Team
Meet the leaders behind Exin Therapeutics
Dr. Gabriel Ocana Santero
Dr. Ivan Lazarte
Marko Tvrdic
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Exin Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Uncommon Therapeutics
Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Compare Exin Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Exin Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Exin Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Exin Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →